Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • Reversine: Precision Aurora Kinase Inhibitor for Cancer R...

    2025-12-25

    Reversine: Precision Aurora Kinase Inhibitor for Cancer Research

    Executive Summary: Reversine (A3760, APExBIO) is a synthetic small molecule that inhibits Aurora kinases A, B, and C with IC50 values of 150 nM, 500 nM, and 400 nM, respectively, disrupting mitotic progression and cell cycle checkpoints (APExBIO; Jan et al., 2025). The compound is insoluble in water but highly soluble in DMSO and ethanol, supporting diverse assay formats. Reversine induces dedifferentiation in murine myoblasts and inhibits proliferation in cervical cancer cell lines, with robust anti-tumor effects in vivo. In murine cervical cancer models, it synergizes with aspirin to reduce tumor mass via apoptosis induction. Reversine is for research use only and is not intended for diagnostic or therapeutic applications.

    Biological Rationale

    Aurora kinases (A, B, C) are serine/threonine kinases essential for mitotic regulation, including centrosome maturation, spindle assembly, and chromosome segregation (Jan et al., 2025). Dysregulation of the Aurora kinase signaling pathway is frequently observed in human cancers and correlates with chromosomal instability and aneuploidy. Inhibition of these kinases disrupts mitotic fidelity, impairs the spindle assembly checkpoint, and induces apoptosis in rapidly proliferating cancer cells. Reversine's specificity for Aurora kinases makes it a valuable chemical probe for studying mitotic checkpoints and the molecular mechanisms underlying cancer cell proliferation inhibition (see guide on workflow optimization).

    Mechanism of Action of Reversine

    Reversine (6-N-cyclohexyl-2-N-(4-morpholin-4-ylphenyl)-7H-purine-2,6-diamine) operates as an ATP-competitive Aurora kinase inhibitor. It binds the kinase domain, blocking ATP access and preventing phosphorylation of critical mitotic substrates. IC50 values for Aurora A, B, and C are 150 nM, 500 nM, and 400 nM, respectively, as determined by in vitro kinase assays at 25°C in Tris-HCl buffer pH 7.5 (APExBIO). Inhibition of Aurora B leads to failed cytokinesis, polyploidy, and activation of the spindle assembly checkpoint, while Aurora A inhibition impairs centrosome maturation and bipolar spindle formation. These effects culminate in cell cycle arrest and programmed cell death (apoptosis induction in cancer cells). Notably, reversine is cell-permeable and active at sub-micromolar concentrations in multiple human and murine cancer cell lines (in-depth mechanistic insights).

    Evidence & Benchmarks

    • Reversine inhibits Aurora kinase A (IC50 = 150 nM), B (IC50 = 500 nM), and C (IC50 = 400 nM) in enzymatic assays at pH 7.5, 25°C (APExBIO).
    • In murine myoblasts, reversine induces dedifferentiation and loss of lineage markers in vitro (Jan et al., 2025, https://doi.org/10.1063/5.0269550).
    • Treatment of HeLa, U14, Siha, Caski, and C33A cervical cancer cells with reversine at 0.5–10 μM leads to significant inhibition of proliferation and induction of apoptosis within 24–72 hours (advanced model applications).
    • In vivo, co-administration of reversine and aspirin in murine cervical cancer models at 2–10 mg/kg (intraperitoneal, daily, 21 days) reduces tumor weight and volume, with synergistic effects on growth inhibition and apoptosis (Jan et al., 2025).
    • Reversine is highly soluble in DMSO (≥19.65 mg/mL) and ethanol (≥6.69 mg/mL with warming and ultrasonication), but insoluble in water; solutions are unstable for long-term storage (APExBIO).

    Applications, Limits & Misconceptions

    Reversine is used for dissecting mitotic regulation and cell cycle checkpoint integrity in cancer and stem cell systems. Its potency enables high-fidelity modeling of Aurora kinase pathway inhibition in both 2D gastruloid and standard adherent cell cultures. The compound is especially valuable in cervical cancer research and for evaluating combinatorial regimens with established therapeutics. For deeper workflow strategies, see this article on workflow integration, which this dossier extends by benchmarking in vivo synergy and specifying storage/solubility parameters.

    Common Pitfalls or Misconceptions

    • Reversine is not soluble in aqueous buffers; improper solvent selection may result in precipitation and loss of activity.
    • It does not selectively inhibit only one Aurora kinase isoform; it targets A, B, and C with varying potency.
    • Solutions of reversine are unstable for long-term storage and should be freshly prepared before use.
    • The product is not intended for diagnostic or therapeutic use in humans or animals.
    • Effects in non-cancerous primary cells may differ; context- and dose-dependent toxicity should be empirically validated.

    Workflow Integration & Parameters

    Reversine is supplied as a solid by APExBIO and should be stored at -20°C, protected from light and moisture. For cell-based assays, dissolve reversine in DMSO (≥19.65 mg/mL) or ethanol (≥6.69 mg/mL with gentle warming and ultrasonic treatment). For in vitro kinase assays, dilute stock solutions in appropriate buffer immediately before use. Recommended working concentrations are 0.1–10 μM for cellular models and 2–10 mg/kg in vivo, but optimization is required for each system. Avoid repeated freeze-thaw cycles and do not store diluted solutions for extended periods. For detailed troubleshooting and advanced application scenarios, consult this workflow guide, which this article updates by reporting validated in vivo synergy and specifying solubility nuances.

    Conclusion & Outlook

    Reversine (A3760, APExBIO) is a validated, cell-permeable Aurora kinase inhibitor that enables precise interrogation of mitotic regulation, cell cycle checkpoints, and apoptosis induction in cancer research. Its robust activity against Aurora kinases A, B, and C, combined with demonstrated efficacy in both in vitro and in vivo models, supports its ongoing utility in translational oncology and developmental biology. Future directions include expanded profiling in 3D organoid and gastruloid systems, as highlighted in recent high-throughput screening studies (Jan et al., 2025), and exploration of combinatorial regimens for overcoming therapeutic resistance. For full technical specifications, refer to the Reversine product page.